Breast cancer immunotherapy: Current biomarkers and the potential of in vitro assays

Melissa C. Skala; Jose M. Ayuso; Mark E. Burkard; Dustin A. Deming

doi:10.1016/j.cobme.2021.100348

Back

Breast cancer immunotherapy: Current biomarkers and the potential of in vitro assays

Journal article

Peer reviewed

Breast cancer immunotherapy: Current biomarkers and the potential of in vitro assays

Melissa C. Skala, Jose M. Ayuso, Mark E. Burkard and Dustin A. Deming

Current opinion in biomedical engineering, Vol.21, p.100348

03/01/2022

DOI: 10.1016/j.cobme.2021.100348

PMCID: PMC8654237

PMID: 34901585

View Online

Abstract

Breakthroughs in metastatic breast cancer care require new model systems that can identify the unique features and vulnerabilities of each cancer. Primary tumor cultures are proposed to efficiently screen multiple treatment options in a patient-specific strategy to maximize therapeutic benefit, minimize toxicity, and enable mechanistic insights that inspire future biomarkers for patient selection. To realize the potential of patient-specific cultures, new tools are needed to capture cell-by-cell variability in behavior and dynamic response to treatments in living 3D specimens. Potential bioengineering tools that can achieve this include optical microscopy to image single-cell dynamics and microphysiological in vitro systems to evaluate cell–cell interactions and immunotherapies. [Display omitted] •Current breast cancer biomarkers do not fully capture clinical variability.•Functional biomarkers can help select patients for breast cancer immunotherapy.•Optical metabolic imaging monitors cellular heterogeneity in cancer.•Microphysiological systems model interactions between cancer and immune cells.

Cancer immunotherapy

Cellular heterogeneity

Microfluidic systems

Microscopy

Patient-derived cancer organoids

Details

Title: Subtitle: Breast cancer immunotherapy: Current biomarkers and the potential of in vitro assays
Creators: Melissa C. Skala - Morgridge Institute for Research
Jose M. Ayuso - University of Wisconsin–Madison
Mark E. Burkard - University of Wisconsin Carbone Cancer Center
Dustin A. Deming - University of Wisconsin Carbone Cancer Center
Resource Type: Journal article
Publication Details: Current opinion in biomedical engineering, Vol.21, p.100348
DOI: 10.1016/j.cobme.2021.100348
PMID: 34901585
PMCID: PMC8654237
NLM abbreviation: Curr Opin Biomed Eng
ISSN: 2468-4511
eISSN: 2468-4511
Publisher: Elsevier Inc
Language: English
Date published: 03/01/2022
Academic Unit: Internal Medicine
Record Identifier: 9984700653802771

Metrics

14 Record Views

5 Times Cited - Web of Science

See more details